ESR1 and breast cancer: In this retrospective study, we used ddPCR to investigate the clinical significance of tracking four representative types of ESR1 LBD mutations in 253 plasma samples from 119 breast cancer patients, of which 99 were from 42 MBC patients and 154 were from 77 advanced ER-positive primary breast cancer (PBC) patients.